Skip to main content
. 2023 Apr 5;38(3):160–172. doi: 10.1089/cbr.2022.0060

FIG. 6.

FIG. 6.

(A) Traditional BNCT drug has a 3:1 ratio of BPA in tumor (dark blue) versus normal brain (blue) at L-BPA dose of 250 mg/kg (patients data); (B) proposed nanodrug has a 16:1 ratio of BPA in tumor versus healthy brain with L-BPA at a dose of 50 mg/kg (animal study).